MiMedx Revenue and Competitors

Atlanta, GA USA

Location

$261.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • MiMedx's estimated annual revenue is currently $137.3M per year.(i)
  • MiMedx's estimated revenue per employee is $179,751
  • MiMedx's total funding is $261.8M.

Employee Data

  • MiMedx has 764 Employees.(i)
  • MiMedx grew their employee count by -4% last year.

MiMedx's People

NameTitleEmail/Phone
1
Associate VP, Global Regulatory AffairsReveal Email/Phone
2
Associate VP - Customer InsightsReveal Email/Phone
3
VPReveal Email/Phone
4
Chief Operating OfficerReveal Email/Phone
5
Area VP, Agency Sales East, MiMedxReveal Email/Phone
6
Associate VP Clinical OperationsReveal Email/Phone
7
Area VPReveal Email/Phone
8
Chief EngineerReveal Email/Phone
9
Chief Financial OfficerReveal Email/Phone
10
Sr. VP SalesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$63.5M2533%N/AN/A
#2
$175.9M993-1%$375MN/A
Add Company

What Is MiMedx?

MiMedx® is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. ?Innovations in Regenerative Medicine? is the framework behind our mission to provide physicians with products and tissues to help the body heal itself. We process human placental tissue utilizing our proprietary PURION® process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be the leader in placental based products with over 40 scientific and clinical publications contained in our Compendium, six completed and published Randomized Controlled Trials (RCTs), and 30 ongoing clinical studies. MiMedx has over 45 placental tissue issued and allowed patents on our products and technologies, with over 90 pending applications. We have continued to demonstrate this leadership by publishing a Primer to educate the medical community on the regenerative aspects of amniotic membrane allografts. MiMedx has supplied over 1 million placental tissue-based allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

keywords:N/A

$261.8M

Total Funding

764

Number of Employees

$137.3M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

MiMedx News

2022-04-19 - ReShape Lifesciences (OTCMKTS:RSLS) and MiMedx Group ...

Comparatively, 19.8% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments...

2022-04-06 - Marietta’s MiMedx moving past recent woes

The new treatment is made from placental tissue that has been ground into a powder, added to a liquid solution and injected at the source of...

2022-03-30 - MIMEDX to Present Health Economics Clinical Data for EPIFIX ...

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected,...

2020-07-02 - MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings

Jul 02 2020 Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management. EW Healthcare Partners Managing Director and Co-Founder Martin Sutter and Former Medtronic Chairman and CEO William Hawkins to Join MiMedx Board of Directors MARIETTA, Georgia(G ...

2020-07-02 - MIMEDX GROUP, INC. MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings

Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management EW Healthcare Partners Managing Director and Co-Founder Martin Sutter and Former Medtronic Chairman and CEO William Hawkins to Join MiMedx Board of Directors MARIETTA, Ga., July 02, 2020 (GL ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$803.7M8085%N/A
#2
$326.6M8644%N/A
#3
$210.5M87411%N/A
#4
$360.6M954-2%N/A
#5
$371.6M983N/AN/A